WO1995001362A1 - Liponucleotide von desoxynucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel - Google Patents
Liponucleotide von desoxynucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel Download PDFInfo
- Publication number
- WO1995001362A1 WO1995001362A1 PCT/EP1994/002123 EP9402123W WO9501362A1 WO 1995001362 A1 WO1995001362 A1 WO 1995001362A1 EP 9402123 W EP9402123 W EP 9402123W WO 9501362 A1 WO9501362 A1 WO 9501362A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- substituted
- liponucleotides
- pyridine
- group
- Prior art date
Links
- 0 **CC(COP(O)(OCC(C(C12)N=O)O*1C2N(C=C(*)C(N1)=*)C1=O)=*)** Chemical compound **CC(COP(O)(OCC(C(C12)N=O)O*1C2N(C=C(*)C(N1)=*)C1=O)=*)** 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to new phospholipid derivatives of deoxynucleosides and ⁇ -D-arabinofuranosylpyrimidines which link a lipid part which is a substituted Cg backbone via a phosphate or thiophosphate to a corresponding nucleoside, and their use as antiviral drugs.
- the invention relates to compounds of the formula I
- C ..- Cg-alkoxycarbonyl, C ⁇ Cg-alkylsulfinyl or Ci-Cß-alkylsulfonyl groups can be substituted
- R represents a straight-chain or branched, saturated or unsaturated aliphatic radical having 1-20 carbon atoms which is optionally substituted one or more times by phenyl, halogen, C j -CG-alkoxy, C ⁇ -C6-Alkylmer- Capto, C 1 -Cg alkoxycarbonyl or C4
- -Cg-alkylsulfonyl groups can be substituted,
- R is a straight-chain or branched C 5 -C 8 alkyl, C 2 -C 7 alkenyl or
- R represents oxygen or the imino group
- X represents a valence line, oxygen, sulfur, sulfinyl or sulfonyl
- Y has the same meaning as X, where the two groups X and Y can be the same or different,
- Z can be oxygen or sulfur
- Patent application PCT / EP91 / 01541 describes liponucleotides with a cyclic sugar part in the nucleoside with antiviral activity.
- New cytarabine derivatives with cytostatic activity are described in DE-OS 4111730. These compounds are not substituted in the 5 position of the base.
- the ether / thioether lipids of the present invention are new and also have valuable pharmacological properties. They are particularly suitable for the therapy and prophylaxis of infections caused by DNA viruses such as e.g. the herpes simplex virus, the cytomegalovirus, Papova viruses, the varicella zoster virus, hepatitis VB / C virus or Epstein-Barr virus or RNA viruses such as toga viruses or retroviruses like the Onko -Viruses HTLV-I and II, as well as the lentiviruses Visna and human immunodeficiency virus HIV-1 and 2, are caused.
- DNA viruses such as e.g. the herpes simplex virus, the cytomegalovirus, Papova viruses, the varicella zoster virus, hepatitis VB / C virus or Epstein-Barr virus or RNA viruses such as toga viruses or retroviruses like the Onko -Viruses HTLV-I
- the compounds of the formula appear particularly suitable for the treatment of the clinical manifestations of viral herpes infection in humans, i.a. also in AIDS patients.
- the compounds of the general formula have an antiviral effect without being unspecifically cytotoxic in pharmacologically relevant doses.
- the compounds of the formula I are also suitable for the treatment of hyperlipidemia, in particular hypercholesterolemia.
- the substances mentioned are inactivators / inhibitors of uracil reductase and are therefore suitable on the basis of their antitumor activity for the treatment of malignancies Diseases. Due to the inactivating properties of uracil reductase, the compounds mentioned can also be used for the therapy of organ-specific and generalized autoimmune diseases, such as psoriasis, systemic lupus erythematosus, rheumatoid arthritis and other autoimmune diseases.
- the compounds are furthermore distinguished by very good oral tolerance with good bioavailability.
- the compounds of the present invention and their pharmaceutical preparations can also be used in combination with other medicaments for the treatment and prophylaxis of the above-mentioned infections.
- these further drugs involve agents that accompanying the treatment and prophylaxis of HIV infections or disease conditions are used such as 3'-azido-3'-deoxythymidine, 2, 3'-dideoxynucleosides such.
- the compounds of the present invention and the other drug (s) can each be administered individually, at the same time optionally in a single or separate formulations or at different times.
- Possible salts of the compounds of the general formula are, in particular, alkali metal, alkaline earth metal and ammonium salts of the phosphate group.
- Lithium, sodium and potassium salts are preferred as alkali salts.
- Magnesium and calcium salts are particularly suitable as alkaline earth metal salts.
- ammonium salts are understood to be salts which contain the ammonium ion, which can be substituted up to four times by alkyl radicals with 1-4 carbon atoms and / or aralkyl radicals, preferably benzyl radicals.
- the substituents can be the same or different.
- R preferably denotes a straight-chain C 8 -C 14 alkyl group which can also be substituted by a C 1 -C 6 alkoxy or a C 1 -C 6 alkyl mercapto group.
- R represents in particular a decyl
- R preferably come the methoxy, ethoxy, butoxy and
- R preferably denotes a straight-chain C 8 -C 14 alkyl group which can also be substituted by a C 1 -C 6 -alkoxy group or a C 1 -C 6 -alkyl mercapto group.
- R represents in particular a decyl, undecyl, dodecyl, tridecyl or tetra
- C ⁇ -Cg alkoxy substituents of R are preferably
- R is substituted by a C 1 -C 6 -alkyl mercapto residue, this means in particular the methyl mercapto, ethyl mercapto, butyl mercapto and hexyl mercapto residue.
- R is preferably oxygen
- X and Y preferably represent an oxygen or sulfur atom
- Z is preferably an oxygen atom
- R preferably represents an unsaturated hydrocarbon radical which, in the case of
- Alkenyls can be substituted by halogen, in particular bromine, and particularly preferably an alkynyl radical.
- the compounds of the formula can be represented by
- Solvents such as e.g. Toluene, or reacted directly in pyridine and, after hydrolysis, optionally cleaves the oxygen protecting groups in accordance with the methods customary in nucleoside chemistry, or
- the medicaments containing compounds of the formula I for the treatment of viral infections can be administered enterally or parenterally in liquid or solid form.
- the usual forms of application come into question, such as
- Water is preferably used as the injection medium, which contains the additives customary for injection solutions, such as stabilizers, solubilizers and buffers.
- additives are, for example, tartrate and citrate buffers, ethanol, complexing agents such as ethylenediaminetetraacetic acid and their non-toxic salts, high molecular weight polymers such as liquid polyethylene oxide for viscosity regulation.
- Liquid carriers for injection solutions must be sterile and are preferably filled into ampoules.
- Solid carriers are, for example, starch, lactose, mannitol, methyl cellulose, talc, highly disperse silicic acids, higher molecular fatty acids, such as stearic acid, gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high molecular polymers, such as polyethylene glycols, etc.
- Preparations suitable for oral applications can, if desired, contain flavorings or sweeteners.
- the dosage can depend on various factors, such as the mode of administration, species, age or individual condition.
- the compounds according to the invention are usually applied in amounts of 0.1-100 mg, preferably 0.2-80 mg per day and per kg of body weight. It is preferred to distribute the daily dose over 2-5 applications, 1-2 tablets with an active substance content of 0.5-500 mg being administered for each application.
- the tablets can also be retarded, which reduces the number of applications per day to 1-3.
- the active substance content of the retarded tablets can be 2- 1000mg.
- the active ingredient can also be given by continuous infusion, the amounts of 5- 1000 mg per day are usually sufficient.
- the phosphate could be extracted with ether from an aqueous suspension of the residue.
- the evaporation residue of the ether phase was purified by column chromatography on silica gel 60 or RP18. Yield 18.7g (63%), R 0.66 (CH 2 CI 2 / MeOH / H 2 O 6.5 / 2.5 / 0.4) on TLC plates Merck 5715, Kieselge. 60.
- the phosphoric acid ester can be prepared as follows:
- a solution of 770 g of 3-dodecylmercapto-2-decyioxy-1-propanoi and 219 g of 2,6-lutidine in 7.51 toluene is added dropwise at 0-3 ° C. to 322 g of phosphorus oxychloride in 7.51 toluene and then complete addition stirred at 0 ° C for a further 3 h.
- the precipitated hydrochloride is then filtered off with suction, washed with toluene and the filtrate is slowly added to a triethylammonium hydrogen carbonate solution (prepared by units of CO 2 in a mixture of 463 g of triethylamine in 4.51 water until the emulsion remains clear).
- the emulsion is mixed with 3.71 1 N hydrochloric acid and 4.51 saturated sodium chloride solution and broken up by filtration.
- the organic phase is evaporated and the oily residue (900 g) is used directly in the next reaction.
- mice Female Balb / c mice, 6-8 weeks old (Iffa Credo), were given 0.2 ml of a virus-containing spleen supernatant per day i.p. inoculated. The animals were i.p. daily from day 0 (start: 1 h after virus inoculation) to day 13. treated with the substance to be examined in doses of 6.25 mg, 12.5 mg, 25 mg and 50 mg per kg.
- the parameters body weight and small blood count (WBC, RBC, Hb, Hkt, PIt) and on day 14 after killing the animals, the individual spleen weights were determined as parameters for viremia.
- MT2 cells were pre-incubated with the substance to be examined and infected with HIV-1 (HTLV-III-B, MOI 0.03). The supernatant was removed, replaced with medium (including substance) and incubated for 7 days.
- HIV-1 HTLV-III-B, MOI 0.03
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7503270A JPH08512040A (ja) | 1993-07-01 | 1994-06-29 | デオキシヌクレオシドのリポヌクレオチド、それらの製造方法および抗ウイルス薬としてのそれらの用途 |
EP94922244A EP0706530A1 (de) | 1993-07-01 | 1994-06-29 | Liponucleotide von desoxynucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel |
AU73449/94A AU7344994A (en) | 1993-07-01 | 1994-06-29 | Liponucleotides of desoxynucleosides, their preaparation and their use as anti-viral drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4321978.0 | 1993-07-01 | ||
DE4321978A DE4321978A1 (de) | 1993-07-01 | 1993-07-01 | Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995001362A1 true WO1995001362A1 (de) | 1995-01-12 |
Family
ID=6491748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/002123 WO1995001362A1 (de) | 1993-07-01 | 1994-06-29 | Liponucleotide von desoxynucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0706530A1 (de) |
JP (1) | JPH08512040A (de) |
AU (1) | AU7344994A (de) |
CA (1) | CA2165979A1 (de) |
DE (1) | DE4321978A1 (de) |
WO (1) | WO1995001362A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4402492A1 (de) * | 1994-01-28 | 1995-08-03 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von unsymmetrischen Phosphorsäurediestern |
GB9708611D0 (en) * | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
EP1460082A1 (de) * | 2003-03-19 | 2004-09-22 | Heidelberg Pharma Holding GmbH | Phospholipidester von clofarabin-derivate |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0350287A2 (de) * | 1988-07-07 | 1990-01-10 | NeXstar Pharmaceuticals, Inc. | Lipid-Derivate von antiviralen Nukleosiden, liposomale Inkorporation und Verwendungsverfahren |
DE4111730A1 (de) * | 1991-04-10 | 1992-10-15 | Knoll Ag | Neue cytarabin-derivate, ihre herstellung und verwendung |
WO1993000910A1 (en) * | 1991-07-12 | 1993-01-21 | Vical, Inc. | Antiviral liponucleosides: treatment of hepatitis b |
WO1993016092A1 (de) * | 1992-02-12 | 1993-08-19 | Boehringer Mannheim Gmbh | Neue lipidphosphonsäure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel |
WO1993016091A1 (de) * | 1992-02-12 | 1993-08-19 | Boehringer Mannheim Gmbh | Neue liponucleotide, deren herstellung sowie deren verwendung als antivirale arzneimittel |
-
1993
- 1993-07-01 DE DE4321978A patent/DE4321978A1/de not_active Withdrawn
-
1994
- 1994-06-29 EP EP94922244A patent/EP0706530A1/de not_active Withdrawn
- 1994-06-29 JP JP7503270A patent/JPH08512040A/ja active Pending
- 1994-06-29 AU AU73449/94A patent/AU7344994A/en not_active Abandoned
- 1994-06-29 CA CA002165979A patent/CA2165979A1/en not_active Abandoned
- 1994-06-29 WO PCT/EP1994/002123 patent/WO1995001362A1/de not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0350287A2 (de) * | 1988-07-07 | 1990-01-10 | NeXstar Pharmaceuticals, Inc. | Lipid-Derivate von antiviralen Nukleosiden, liposomale Inkorporation und Verwendungsverfahren |
DE4111730A1 (de) * | 1991-04-10 | 1992-10-15 | Knoll Ag | Neue cytarabin-derivate, ihre herstellung und verwendung |
WO1992018520A1 (de) * | 1991-04-10 | 1992-10-29 | Knoll Ag | Neue cytarabin-derivate, ihre herstellung und verwendung |
WO1993000910A1 (en) * | 1991-07-12 | 1993-01-21 | Vical, Inc. | Antiviral liponucleosides: treatment of hepatitis b |
WO1993016092A1 (de) * | 1992-02-12 | 1993-08-19 | Boehringer Mannheim Gmbh | Neue lipidphosphonsäure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel |
WO1993016091A1 (de) * | 1992-02-12 | 1993-08-19 | Boehringer Mannheim Gmbh | Neue liponucleotide, deren herstellung sowie deren verwendung als antivirale arzneimittel |
Also Published As
Publication number | Publication date |
---|---|
DE4321978A1 (de) | 1995-01-12 |
EP0706530A1 (de) | 1996-04-17 |
CA2165979A1 (en) | 1995-01-12 |
AU7344994A (en) | 1995-01-24 |
JPH08512040A (ja) | 1996-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0545966B1 (de) | Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel | |
WO1993016092A1 (de) | Neue lipidphosphonsäure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel | |
WO1993016091A1 (de) | Neue liponucleotide, deren herstellung sowie deren verwendung als antivirale arzneimittel | |
DE69531749T2 (de) | Nukleosid-Monophosphatderivate, Verfahren zu deren Herstellung sowie deren Verwendung als Immunsuppressive Arzneimittel | |
CH626363A5 (de) | ||
EP0355031A2 (de) | Substituierte Pyrimidinnucleoside, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel | |
EP0416401B1 (de) | Verwendung von Phospholipid-Derivaten als antivirale Arzneimittel und neue Phospholipide | |
EP0868425B1 (de) | Phospholipid-derivate von phosphonocarbonsäuren, deren herstellung sowie deren verwendung als antivirale arzneimittel | |
EP0817790B1 (de) | Spezifische lipidkonjugate von nucleosid-diphosphaten und deren verwendung als arzneimittel | |
EP0654036B1 (de) | Liponucleotide von seco-nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel | |
WO1995001362A1 (de) | Liponucleotide von desoxynucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel | |
DE602004001047T2 (de) | Phospholipidester von Clofarabin | |
EP0854708B1 (de) | Lipidalkohole als neue immunsuppressive und antivirale arneimittel | |
EP0869817B1 (de) | Kovalente lipid-phosphonocarbonsäure-konjugate und ihre anwendung als antivirale arzneimittel | |
DE4021006A1 (de) | Pyrimidin-derivate, deren herstellung und verwendung sowie diese enthaltende arzneimittel | |
EP0080305A1 (de) | Antivirale 2'-Deoxyuridine, ihre Herstellung und Verwendung | |
AT392794B (de) | Verfahren zur herstellung von neuen pharmazeutisch annehmbaren estern und salzen von 3'-azido-3'-desoxythymidin | |
CZ18093A3 (en) | Novel derivatives of phospholipid nucleosides, process of their preparation as well as their use as antiviral medicaments | |
DE3048873A1 (de) | Alkyl- und alkenylpyrimidinnucleosid-phosphonate, verfahren zur herstellung und sie enthaltende mittel | |
DE3931557A1 (de) | Neue 2',3'-anhydro-nukleoside, verfahren zu deren herstellung sowie arzneimittel, die diese verbindungen enthalten | |
DE19547023A1 (de) | Neue Phospholipid-Derivate von Phosphonocarbonsäuren, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel | |
DE19643416A1 (de) | Neue Phospholipid-Derivate von Phosphonocarbonsäuren, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR CA CN CZ FI HU JP KR KZ NO NZ PL RO RU SI SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994922244 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2165979 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1995 564272 Country of ref document: US Date of ref document: 19951228 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1994922244 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994922244 Country of ref document: EP |